The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
|Articles|May 31, 2022
“I Think I am Probably the Happiest Ileal Conduit Person in the World” with Vicki S.
Advertisement
In this special episode of Bladder Cancer Matters, BCAN associate Joslyn Brown has a frank and uplifting conversation with Vicki S., who declares herself to be the “luckiest ileal conduit person in the world.” Joslyn and Vicki talk about:
- The symptoms that Vicki had well before her bladder removal surgery
- How relieved she was to have her bladder taken out
- What her recovery was like
- How happy she is to be alive and doing well after her surgery
We also encourage you to visit our web site for additional information about bladder removal surgery (
Advertisement
Related to this article
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
Anktiva for Papillary Bladder Cancer: What Patients Should Know
5